UFlex Limited Q2 FY26 Concall Decoded: Volumes at record highs, guidance quietly cut, and debt doing the heavy lifting—while management insists the cycle will turn.

1. Opening Hook

UFlex walked into Q2 FY26 after battling tariffs, GST confusion, extended monsoons, Chinese dumping, European chaos, and analysts armed with peer comparisons.
The verdict? “Decent quarter.”
Which, in corporate language, means: could’ve been worse, but don’t clap yet.

Revenues stayed flat, EBITDA barely moved, but PAT magically jumped 150%—thanks to forex ghosts leaving the building.
Aseptic volumes hit record highs, but seasonality ensured Q2 looked weaker than Q1.
Meanwhile, imports flooded India, Europe got dumped on, and UFlex decided to lower guidance rather than sugarcoat reality.

Read on—because beneath the calm tone lies a classic cyclical story of capacity, debt, patience, and hoping demand blinks first.

2. At a Glance

• H1 Revenue up 3% – Growth, but only if you squint hard.
• H1 EBITDA up 4% – Inflation punched, margins barely ducked.
• H1 PAT up ~150% – Forex losses exited stage left.
• Aseptic volumes +5.5% YoY – Plants sweating, capacity capped till October.
• FY26 guidance cut to ~5% growth – Management chose realism over optimism.

3. Management’s Key Commentary

“It’s been a decent quarter considering headwinds.”
(Translation: Please factor in everything that went wrong 😏)

“We achieved highest-ever aseptic volumes in H1.”
(Translation: Demand is fine, capacity was the villain.)

“Imports of BOPET up 120%, BOPP up 100% in India.”
(Translation: China and SEA crashed the pricing party.)

“Europe performance was impacted due to diversion of exports.”
(Translation: If the US sneezes, Europe catches a cold.)

“Earlier guidance of 10% revenue growth needs relook.”
(Translation: Let’s not pretend anymore.)

“FY26 EBITDA expected at ₹1,800–1,850 crore.”
(Translation: Lower ambition, higher believability.)

“Debt will reduce by ~₹500 crore by FY27.”
(Translation: Slowly, painfully, but yes.)

4. Numbers Decoded